Results 41 to 50 of about 1,678,208 (198)

Amylin: Pharmacology, Physiology, and Clinical Potential [PDF]

open access: yes, 2015
Amylin is a pancreatic β-cell hormone that produces effects in several different organ systems. Here, we review the literature in rodents and in humans on amylin research since its discovery as a hormone about 25 years ago.
Roth, Jonathan D   +9 more
core   +1 more source

The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy [PDF]

open access: yesThe Journal of Pharmacology and Experimental Therapeutics, 2020
Amylin treatment improves body weight and glucose control, although it is limited by a short action and need for high doses. Dual amylin and calcitonin receptor agonists (DACRAs) are dual amylin and calcitonin receptor agonists with beneficial effects beyond those of amylin. However, to what extent the additional benefits reside in their higher potency
Anna Thorsø Larsen   +4 more
openaire   +5 more sources

Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options

open access: yesMolecules, 2023
Obesity and type 2 diabetes (T2DM) are major public health concerns associated with serious morbidity and increased mortality. Both obesity and T2DM are strongly associated with adiposopathy, a term that describes the pathophysiological changes of the ...
Angelica Artasensi   +4 more
doaj   +1 more source

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders [PDF]

open access: yesClinical and Molecular Hepatology
Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders.
Yun Kyung Cho, Chang Hee Jung
doaj   +1 more source

Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism [PDF]

open access: yes, 2020
The manuscript of a paper entitled "Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism".
Anton, Bashilov   +5 more
core   +2 more sources

Hepatocyte‐Centered Regulation of MASH Fibrosis: From Animal Models to Molecular Mechanisms and Targeted Therapies

open access: yesiNew Medicine, EarlyView.
This review highlights hepatocytes as active regulators of MASH fibrosis through secreted proteins, metabolites, and extracellular vesicles that modulate hepatic stellate cell activation. These hepatocyte–stellate cell communication pathways provide a mechanistic framework for developing targeted antifibrotic therapies, including hepatocyte‐directed ...
Eui Jung Jung, Xiaobo Wang
wiley   +1 more source

Biochemical pharmacology of the positive allosteric modulation of the GABAb receptor "in Vitro" and "in Vivo" [PDF]

open access: yes, 2007
Allosteric modulators of G-protein coupled receptors (GPCRs) interact with binding sites on the receptor molecule that are topographically distinct from the classic orthosteric site.
Gjoni, Tina
core   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines

open access: yesScientia Pharmaceutica
Once-monthly injectable therapies targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and adjacent metabolic pathways are moving from a conceptual goal to a plausible next step for type 2 diabetes (T2D) and ...
Héctor Iván Saldívar-Cerón
doaj   +1 more source

Home - About - Disclaimer - Privacy